Ikaros Proteins in Tumor: Current Perspectives and New Developments
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Authors
Keywords
-
Journal
Frontiers in Molecular Biosciences
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-07
DOI
10.3389/fmolb.2021.788440
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
- (2021) Marco Cippitelli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Hsp90/C terminal Hsc70-interacting protein regulates the stability of Ikaros in acute myeloid leukemia cells
- (2021) Meng Liu et al. Science China-Life Sciences
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
- (2021) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Circulating epigenetic biomarkers for detection of recurrent colorectal cancer
- (2020) Erin L. Symonds et al. CANCER
- Expression, mutation, and methylation of crbn‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma
- (2020) Takuto Tachita et al. CANCER SCIENCE
- Transcriptional Regulation of Genes by Ikaros Tumor Suppressor in Acute Lymphoblastic Leukemia
- (2020) Pavan Kumar Dhanyamraju et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Regulation of Small GTPase Rab20 by Ikaros in B-Cell Acute Lymphoblastic Leukemia
- (2020) Jonathon L Payne et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
- (2020) Joshua D. Hansen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
- (2020) Joshua F. Zeidner et al. LEUKEMIA
- Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
- (2020) G. J. Ossenkoppele et al. LEUKEMIA
- Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
- (2020) Nizar J. Bahlis et al. LEUKEMIA
- Combination lenalidomide/bortezomib treatment synergistically induces calpain-dependent Ikaros cleavage and apoptosis in myeloma cells
- (2020) Saravanan Ganesan et al. MOLECULAR CANCER RESEARCH
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- Lenalidomide in follicular lymphoma
- (2020) Christopher Flowers et al. BLOOD
- IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly
- (2020) Stephanie Vairy et al. BLOOD REVIEWS
- The correlation of helios and neuropilin-1 frequencies with parkinson disease severity
- (2020) Reza Daneshvar Kakhaki et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro
- (2020) Xiaofei He et al. EXPERIMENTAL HEMATOLOGY
- Management of Chronic Immune Thrombocytopenia and Presumed Autoimmune Hepatitis in a Child with IKAROS Haploinsufficiency
- (2020) Daniel J. Groth et al. JOURNAL OF CLINICAL IMMUNOLOGY
- IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia
- (2020) Melissa Granados-Zamora et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
- (2020) Teru Hideshima et al. LEUKEMIA
- Covid-19, Angiogenesis, and ARDS Endotypes
- (2020) Lida Hariri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integration of high-throughput reporter assays identify a critical enhancer of the Ikzf1 gene
- (2020) Jaafar Alomairi et al. PLoS One
- Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
- (2020) Brian G. M. Durie et al. Blood Cancer Journal
- Enrichment of atypical hyperdiploidy and IKZF1 deletions detected by SNP-microarray in high-risk Australian AIEOP-BFM B-cell acute lymphoblastic leukaemia cohort
- (2020) Nadine K Berry et al. Cancer Genetics
- Ikaros is heterogeneously expressed in lung adenocarcinoma and is involved in its progression
- (2020) Wei Zhao et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance
- (2020) Jianxuan Zou et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- (2020) Meletios Dimopoulos et al. LANCET
- A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma
- (2020) Go Woon Kim et al. LEUKEMIA RESEARCH
- Clinical value of RAG1 expression and IKZF1 deletions in Philadelphia negative pediatric B cell precursor acute lymphoblastic leukemia
- (2020) Salah Aref et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling
- (2020) Ipsita Guha et al. Frontiers in Immunology
- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
- (2020) Saad Z Usmani et al. Lancet Haematology
- Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study
- (2020) Jean-Marie Michot et al. Lancet Haematology
- Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses
- (2020) Vien Phan et al. Blood Advances
- GSK3β-Ikaros-ANXA4 signaling inhibits high-glucose-induced fibroblast migration
- (2020) Youpei Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A randomized phase-2 trial of pomalidomide in subjects failing prior therapy of chronic graft-versus-host disease
- (2020) Lauren M Curtis et al. BLOOD
- Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
- (2020) Meletios A Dimopoulos et al. BLOOD
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
- (2020) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- The specific distribution pattern of IKZF1 mutation in acute myeloid leukemia
- (2020) Xiang Zhang et al. Journal of Hematology & Oncology
- Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- IKZF1 polymorphisms are associated with susceptibility, cytokine levels, and clinical features in systemic lupus erythematosus
- (2020) Lin Chen et al. MEDICINE
- Ginseng polysaccharide inhibits MDA‑MB‑231 cell proliferation by activating the inflammatory response
- (2020) Haoliang Zhou et al. Experimental and Therapeutic Medicine
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
- (2020) Meletios A. Dimopoulos et al. Blood Cancer Journal
- Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis
- (2020) Alli Murugesan et al. JOURNAL OF NATURAL PRODUCTS
- Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4
- (2020) Kyoko Ochiai et al. Cell Reports
- Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
- (2020) Paola Tacchetti et al. Lancet Haematology
- Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial
- (2020) Marco Ladetto et al. Lancet Haematology
- Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
- (2020) Saad Z Usmani et al. Lancet Haematology
- Innate lymphoid cells: from helper to killer
- (2020) Lisette Krabbendam et al. CURRENT OPINION IN IMMUNOLOGY
- The Making of a Leukemic Stem Cell: A Novel Role for IKZF2 in AML Stemness and Differentiation
- (2019) Steven M. Chan Cell Stem Cell
- Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
- (2019) Charles Craddock et al. JOURNAL OF CLINICAL ONCOLOGY
- Lack of Ikaros Deregulates Inflammatory Gene Programs in T Cells
- (2019) Carolina Lyon de Ana et al. JOURNAL OF IMMUNOLOGY
- Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS
- (2019) Stefania Fiorcari et al. LEUKEMIA
- Overexpression of Aiolos promotes epithelial-mesenchymal transition and cancer stem cell-like properties in lung cancer cells
- (2019) Jung-Jyh Hung et al. Scientific Reports
- Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
- (2019) Yuan Xiao Zhu et al. Blood Cancer Journal
- Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
- (2019) Katharina Kriegsmann et al. Blood Cancer Journal
- RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
- (2019) Nan Zhou et al. LEUKEMIA
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
- (2019) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- The genetic variants of IKZF1 gene linked with the growing risk of childhood acute lymphoblastic leukaemia
- (2019) Safaa I. Tayel et al. CURRENT MOLECULAR MEDICINE
- Cuplike nuclear morphology is highly associated with IKZF1 deletion in pediatric precursor B-cell ALL
- (2019) Weijie Li et al. BLOOD
- IKZF1 Loss-of-Function Variant Causes Autoimmunity and Severe Familial Antiphospholipid Syndrome
- (2019) Yannick Dieudonné et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity
- (2019) Yali Ding et al. LEUKEMIA
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hide and seek: Plasticity of innate lymphoid cells in cancer
- (2019) Tobias Bald et al. SEMINARS IN IMMUNOLOGY
- Analysis of Regulatory T Cell Subsets and Their Expression of Helios and PD-1 in Patients with Hashimoto Thyroiditis
- (2019) Yifang Hu et al. International Journal of Endocrinology
- Familial Immune Thrombocytopenia Associated With a Novel Variant in IKZF1
- (2019) Panida Sriaroon et al. Frontiers in Pediatrics
- N160 of Aiolos Determines its DNA‐Binding Activity
- (2019) Hao Wang et al. Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology
- Germline mutations in the transcription factor IKZF5 cause thrombocytopenia
- (2019) Claire Lentaigne et al. BLOOD
- Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3−ILC1/NK cell transdifferentiation
- (2019) Luca Mazzurana et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma
- (2019) Hye‑Rim Won et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Selective deletion of Eos (Ikzf4) in T-regulatory cells leads to loss of suppressive function and development of systemic autoimmunity
- (2019) Ameya S. Gokhale et al. JOURNAL OF AUTOIMMUNITY
- Deregulation of Ikaros expression in B‐1 cells: New insights in the malignant transformation to chronic lymphocytic leukemia
- (2019) Vivian Cristina de Oliveira et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
- (2019) Jiro Kikuchi et al. LEUKEMIA
- Assessing the Functional Relevance of Variants in the IKAROS Family Zinc Finger Protein 1 (IKZF1) in a Cohort of Patients With Primary Immunodeficiency
- (2019) Zoya Eskandarian et al. Frontiers in Immunology
- Ikaros Zinc Finger Transcription Factors: Regulators of Cytokine Signaling Pathways and CD4+ T Helper Cell Differentiation
- (2019) Michael D. Powell et al. Frontiers in Immunology
- Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. Lancet Haematology
- Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
- (2019) Saad Zafar Usmani et al. Lancet Haematology
- Proteasome Inhibitor Drugs
- (2019) Lloyd D. Fricker Annual Review of Pharmacology and Toxicology
- Huaier extract enhances the treatment efficacy of imatinib in Ik6+ Ph+ acute lymphoblastic leukemia
- (2019) Ping Qu et al. BIOMEDICINE & PHARMACOTHERAPY
- Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma
- (2019) Laura Rosiñol et al. BLOOD
- Detection by a simple and cheaper methodology of Ik6 and Ik10 isoforms of the IKZF1 gene is highly associated with a poor prognosis in B‐lineage paediatric acute lymphoblastic leukaemia
- (2019) Larissa B. P. Moreira et al. BRITISH JOURNAL OF HAEMATOLOGY
- Helios: Still Behind the Clouds
- (2019) Angela M. Thornton et al. IMMUNOLOGY
- Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R− Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity
- (2019) Prossy Naluyima et al. JOURNAL OF IMMUNOLOGY
- PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia
- (2019) Kazuki Okuyama et al. PLoS Genetics
- Declining Pulmonary Function in Interstitial Lung Disease Linked to Lymphocyte Dysfunction
- (2019) Cody A. Schott et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Downregulation of miR-4772-3p promotes enhanced regulatory T cell capacity in malignant pleural effusion by elevating Helios levels
- (2019) Wen-Qing Yu et al. CHINESE MEDICAL JOURNAL
- Ikzf1 regulates embryonic T lymphopoiesis via Ccr9 and Irf4 in zebrafish
- (2019) Youkui Huang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
- (2019) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Ikaros prevents autoimmunity by controlling anergy and Toll-like receptor signaling in B cells
- (2019) Tanja A. Schwickert et al. NATURE IMMUNOLOGY
- Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
- (2019) Pedro Mogollón et al. Cells
- Epstein-Barr Virus BART Long Non-coding RNAs Function as Epigenetic Modulators in Nasopharyngeal Carcinoma
- (2019) Rob J. A. Verhoeven et al. Frontiers in Oncology
- Helios enhances the preferential differentiation of human fetal CD4+ naïve T cells into regulatory T cells
- (2019) Melissa S. F. Ng et al. Science Immunology
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- EOS, an Ikaros family zinc finger transcription factor, interacts with the HTLV-1 oncoprotein Tax and is downregulated in peripheral blood mononuclear cells of HTLV-1-infected individuals, irrespective of clinical statuses
- (2019) Tadasuke Naito et al. Virology Journal
- BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach
- (2019) TAKU TSUKAMOTO et al. Cancer Genomics & Proteomics
- Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia
- (2018) Michelle L. Churchman et al. CANCER CELL
- B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies
- (2018) Gang Xiao et al. CELL
- Polymorphisms of IKZF3 Gene and Autoimmune Thyroid Diseases: Associated with Graves’ Disease but Not with Hashimoto’s Thyroiditis
- (2018) Ling Li et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- The Ikaros family in lymphocyte development
- (2018) Beate Heizmann et al. CURRENT OPINION IN IMMUNOLOGY
- Molecular Regulation of Differentiation in Early B-Lymphocyte Development
- (2018) Mikael Sigvardsson INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- IKZF1plus Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
- (2018) Martin Stanulla et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Targeting MYC in multiple myeloma
- (2018) K. K. Jovanović et al. LEUKEMIA
- Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma
- (2018) Konstantinos Dimopoulos et al. LEUKEMIA & LYMPHOMA
- Leukaemic alterations of IKZF1 prime stemness and malignancy programs in human lymphocytes
- (2018) Zhen Li et al. Cell Death & Disease
- Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia
- (2018) Zheng Ge et al. Epigenomics
- Circulating tumour DNA for monitoring colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection
- (2018) Erin L. Symonds et al. Clinical Epigenetics
- Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
- (2018) Aude Le Roy et al. Frontiers in Immunology
- IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy
- (2018) James C. Chen et al. Cell Systems
- Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
- (2018) Jia Ruan et al. BLOOD
- IMiDs through loss of Ikaros and Aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD38
- (2018) Pasquale L. Fedele et al. BLOOD
- Innate Lymphoid Cells: 10 Years On
- (2018) Eric Vivier et al. CELL
- Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study
- (2018) Allen Eng Juh Yeoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- (2018) Franck Morschhauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Brd4 for cancer therapy: inhibitors and degraders
- (2018) Yingchao Duan et al. MedChemComm
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
- (2018) Laurent Garderet et al. BLOOD
- Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade
- (2018) Jing Zheng et al. CANCER LETTERS
- IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation
- (2018) Sun-Mi Park et al. Cell Stem Cell
- CRLF2 expression associates with ICN1 stabilisation in T-cell acute lymphoblastic leukaemia
- (2018) Ana Luiza Tardem Maciel et al. GENES CHROMOSOMES & CANCER
- Hierarchical assembly and disassembly of a transcriptionally active RAG locus in CD4+CD8+ thymocytes
- (2018) Abani Kanta Naik et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Enhancer Connectome Nominates Target Genes of Inherited Risk Variants from Inflammatory Skin Disorders
- (2018) Mark Y. Jeng et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- (2018) Graham H Jackson et al. LANCET ONCOLOGY
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- IKZF1 deletion and co-occurrence with other aberrations in a child with chronic myeloid leukemia progressing to acute lymphoblastic leukemia
- (2018) Claudete Esteves Klumb et al. PEDIATRIC BLOOD & CANCER
- Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
- (2018) Quinlan L. Sievers et al. SCIENCE
- Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia
- (2018) Zheng Ge et al. Oncogenesis
- Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells
- (2018) David A. Davis et al. OncoImmunology
- Multiple functions of Ikaros in hematological malignancies, solid tumor and autoimmune diseases
- (2018) Qiuni Chen et al. GENE
- Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
- (2017) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2017) Catherine Thieblemont et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
- (2017) Mary E. Matyskiela et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD
- (2017) T Yuan et al. LEUKEMIA
- Overexpression of dominant-negative Ikaros 6 isoform is associated with resistance to TKIs in patients with Philadelphia chromosome positive acute lymphoblastic leukemia
- (2017) Changfeng Shao et al. Experimental and Therapeutic Medicine
- Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
- (2017) Federica Costa et al. Oncotarget
- Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
- (2016) Rachid C. Baz et al. BLOOD
- Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells
- (2016) K-H Hung et al. CELL DEATH AND DIFFERENTIATION
- Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
- (2016) C. Vitale et al. CLINICAL CANCER RESEARCH
- Casein kinase II (CK2) as a therapeutic target for hematological malignancies
- (2016) Chandrika Gowda et al. CURRENT PHARMACEUTICAL DESIGN
- Ikaros Inhibits Group 3 Innate Lymphoid Cell Development and Function by Suppressing the Aryl Hydrocarbon Receptor Pathway
- (2016) Shiyang Li et al. IMMUNITY
- High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
- (2016) Maryam Pourabdollah et al. Journal of Hematology & Oncology
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
- (2016) Mary E. Matyskiela et al. NATURE
- Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
- (2016) Georg Petzold et al. NATURE
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival
- (2016) Hiroto Ohguchi et al. Nature Communications
- Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia
- (2016) Zheng Ge et al. Oncotarget
- High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement
- (2016) Zheng Ge et al. Oncotarget
- Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction
- (2016) Zheng Ge et al. Oncotarget
- The Ikaros family of zinc-finger proteins
- (2016) Yingzhi Fan et al. Acta Pharmaceutica Sinica B
- Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia
- (2016) Zheng Ge et al. Scientific Reports
- Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
- (2015) K. Lagrue et al. BLOOD
- CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
- (2015) P. R. Hagner et al. BLOOD
- Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia
- (2015) C. Song et al. BLOOD
- Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia
- (2015) Michelle L. Churchman et al. CANCER CELL
- Proteasome inhibitors block Ikaros degradation by Lenalidomide in Multiple Myeloma
- (2015) C.-X. Shi et al. HAEMATOLOGICA
- Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia
- (2015) J. D. E. de Rooij et al. HAEMATOLOGICA
- Transcriptional Regulation ofJARID1B/KDM5BHistone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia
- (2015) Haijun Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program
- (2015) Sun-Mi Park et al. JOURNAL OF CLINICAL INVESTIGATION
- Eos Is Redundant for Regulatory T Cell Function but Plays an Important Role in IL-2 and Th17 Production by CD4+Conventional T Cells
- (2015) Sadiye Amcaoglu Rieder et al. JOURNAL OF IMMUNOLOGY
- Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma
- (2015) E Brissot et al. LEUKEMIA
- Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia
- (2015) R Marke et al. LEUKEMIA
- Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia
- (2015) C Song et al. LEUKEMIA
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stable inhibitory activity of regulatory T cells requires the transcription factor Helios
- (2015) H.-J. Kim et al. SCIENCE
- Ethnic-specific associations of rare and low-frequency DNA sequence variants with asthma
- (2015) Catherine Igartua et al. Nature Communications
- Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
- (2015) C C Bjorklund et al. Blood Cancer Journal
- Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia
- (2015) Zheng Ge et al. Oncotarget
- The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
- (2015) Cinzia Fionda et al. Oncotarget
- Proteasome inhibitors block Ikaros degradation by Lenalidomide in Multiple Myeloma
- (2015) C.-X. Shi et al. HAEMATOLOGICA
- Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia
- (2015) J. D. E. de Rooij et al. HAEMATOLOGICA
- Master Regulators of Infiltrate Recruitment in Autoimmune Disease Identified through Network-Based Molecular Deconvolution
- (2015) James C. Chen et al. Cell Systems
- Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression
- (2014) P. A. Beer et al. BLOOD
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- (2014) Y. X. Zhu et al. BLOOD
- Aiolos Promotes Anchorage Independence by Silencing p66Shc Transcription in Cancer Cells
- (2014) Xichuan Li et al. CANCER CELL
- Helios Expression in T-regulatory Cells in Patients with di George Syndrome
- (2014) Adam Klocperk et al. JOURNAL OF CLINICAL IMMUNOLOGY
- In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
- (2014) E M Ocio et al. LEUKEMIA
- Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts
- (2014) A P A Theocharides et al. LEUKEMIA
- Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide
- (2014) Vittorio Montefusco et al. LEUKEMIA & LYMPHOMA
- Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia
- (2014) Ila Joshi et al. NATURE IMMUNOLOGY
- Stage-specific control of early B cell development by the transcription factor Ikaros
- (2014) Tanja A Schwickert et al. NATURE IMMUNOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein Phosphatase 1 (PP1) and Casein Kinase II (CK2) regulate Ikaros-mediated repression ofTdTin thymocytes and T-cell leukemia
- (2014) Haijun Wang et al. PEDIATRIC BLOOD & CANCER
- The IKAROS Interaction with a Complex Including Chromatin Remodeling and Transcription Elongation Activities Is Required for Hematopoiesis
- (2014) Stefania Bottardi et al. PLoS Genetics
- Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Associations of polymorphisms in non-HLA loci with autoantibodies at the diagnosis of type 1 diabetes:INSandIKZF4associate with insulin autoantibodies
- (2013) J Lempainen et al. PEDIATRIC DIABETES
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Unique contribution of IRF-5-Ikaros axis to the B-cell IgG2a response
- (2012) C-M Fang et al. GENES AND IMMUNITY
- FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination
- (2012) Alabbas Alkhatib et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases
- (2012) J-Q Mi et al. LEUKEMIA
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ikaros inhibits proliferation and, through upregulation of Slug, increases metastatic ability of ovarian serous adenocarcinoma cells
- (2012) LI-CAI HE et al. ONCOLOGY REPORTS
- Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros
- (2012) F. M. Uckun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- (2011) P. Fenaux et al. BLOOD
- An Allele ofIKZF1(Ikaros) Conferring Susceptibility to Childhood Acute Lymphoblastic Leukemia Protects Against Type 1 Diabetes
- (2011) Austin D.-E. Swafford et al. DIABETES
- Ikaros, CK2 kinase, and the road to leukemia
- (2011) Sinisa Dovat et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Long-Range Epigenetic Silencing Associates with Deregulation of Ikaros Targets in Colorectal Cancer Cells
- (2011) B. M. Javierre et al. MOLECULAR CANCER RESEARCH
- Cell cycle-specific function of Ikaros in human leukemia
- (2011) Zhanjun Li et al. PEDIATRIC BLOOD & CANCER
- Congenital pancytopenia and absence of B lymphocytes in a neonate with a mutation in the ikaros gene
- (2011) Frederick D. Goldman et al. PEDIATRIC BLOOD & CANCER
- Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy
- (2011) Olga Gorlova et al. PLoS Genetics
- Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with Systemic Lupus Erythematosus
- (2011) Deborah S. Cunninghame Graham et al. PLoS Genetics
- Identification of fusion genes in breast cancer by paired-end RNA-sequencing
- (2011) Henrik Edgren et al. GENOME BIOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL
- (2010) R P Kuiper et al. LEUKEMIA
- Ikaros Stability and Pericentromeric Localization Are Regulated by Protein Phosphatase 1
- (2009) Marcela Popescu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia
- (2009) Charles G. Mullighan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eos Mediates Foxp3-Dependent Gene Silencing in CD4+ Regulatory T Cells
- (2009) F. Pan et al. SCIENCE
- The Aiolos transcription factor is up-regulated in chronic lymphocytic leukemia
- (2008) M. Duhamel et al. BLOOD
- BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3
- (2008) J. Nakayama et al. BLOOD
- Recruitment of Ikaros to Pericentromeric Heterochromatin Is Regulated by Phosphorylation
- (2008) Zafer Gurel et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
- (2008) Charles G. Mullighan et al. NATURE
- Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
- (2008) Jeffrey C Barrett et al. NATURE GENETICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started